Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | IL1RN | P18510 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991758 | 0.84 | CA2 (0.41) | CA2PTGS1PTGS2IL1RNKEAP1 | |
| SCHEMBL13266257 | 0.82 | CA2 (0.42) | CA2PTGS1PTGS2IL1RNKEAP1 | |
| SCHEMBL11559001 | 0.79 | KEAP1 (0.48) | CA2IL1RNKEAP1ERAP1NR1H3 | |
| SCHEMBL17266478 | 0.79 | PTPN1 (0.49) | CA2PTGS1PTGS2IL1RNKEAP1 | |
| SCHEMBL776228 | 0.77 | HTR6 (0.46) | CA2IL1RNKEAP1ERAP1NR1H3 | |
| SCHEMBL18535392 | 0.76 | CA1 (0.48) | CA2IL1RNKEAP1ERAP1NR1H3 | |
| SCHEMBL120712 | 0.76 | CA2 (0.48) | CA2IL1RNKEAP1ERAP1NR1H3 | |
| SCHEMBL2993840 | 0.74 | HTR6 (0.42) | CA2IL1RNKEAP1ERAP1NR1H3 | |
| SCHEMBL2991879 | 0.73 | PTGS1 (0.42) | CA2PTGS1PTGS2PTPN1CA1 | |
| SCHEMBL2988092 | 0.73 | KEAP1 (0.54) | CA2KEAP1CA1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853448-B2 | Aromatic sulfonylimides, preparation thereof and use thereof as electrolyte | INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20100174113-A1 | AROMATIC SULPHONYLIMIDES, PREPARATION THEREOF AND USE THEREOF AS ELECTROLYTE | INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174113-A1 | AROMATIC SULPHONYLIMIDES, PREPARATION THEREOF AND USE THEREOF AS ELECTROLYTE | AFF2, ARSA, FGFR2 | CA2 173/4885PTGS1 4858/4885PTGS2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.